Evonik Breaks Ground on €80 Million Biotechnology Expansion in Slovakia: A New Era for Sustainable Manufacturing

Introduction: Scaling the Future of Bio-Based Chemistry

In a significant move to solidify its position at the vanguard of the global biotechnology sector, German specialty chemicals giant Evonik has officially broken ground on a major expansion project at its Fermas site in Slovenská Ľupča, Slovakia. This €80 million investment represents a strategic pivot toward high-performance, sustainable manufacturing, positioning the Fermas facility as a critical node in the company’s global drug substance and specialty chemical supply chain.

As the life sciences industry grapples with the dual pressures of increasing demand for complex pharmaceutical intermediates and the urgent mandate to decarbonize, Evonik’s latest development offers a roadmap for the future. By integrating state-of-the-art downstream fermentation technology, the company aims to marry industrial-scale output with the precision and environmental benefits of biotechnology.

Main Facts: The Scope of the Investment

The expansion project, which is slated for completion in early 2028, is designed to significantly boost the site’s capacity to handle complex pharmaceutical processes. The core components of the project include:

• Financial Commitment: An approximate €80 million capital expenditure aimed at infrastructure and technological upgrades.
• Technological Integration: The addition of advanced downstream fermentation capacity, which will enable the production of highly specialized pharmaceutical intermediates.
• Economic Impact: The creation of approximately 50 high-skilled jobs in the region, ranging from biotechnology engineers to specialized manufacturing personnel.
• Strategic Objective: Enhancing Evonik’s contract development and manufacturing organization (CDMO) capabilities to support pharmaceutical and nutraceutical clients worldwide.

The facility’s expansion is not merely a capacity increase; it is a qualitative shift. By leveraging fermentation, Evonik can produce molecules that are difficult or impossible to synthesize via traditional organic chemistry, while simultaneously reducing the ecological footprint of the production cycle.

Chronology: From Amino Acids to Biotechnology Hub

The Fermas site in Slovakia has long been a cornerstone of Evonik’s operations, but its trajectory over the last three decades mirrors the broader evolution of the biotechnology industry itself.

1992: The Foundation

The Fermas site was established in 1992, initially focusing on the production of amino acids. At the time, the site was a pioneer in the application of fermentation for food and nutrition-grade ingredients, setting the stage for more complex bioprocesses.

2000s–2010s: Diversification

Over the following decades, the facility transitioned away from commodity production toward higher-margin, specialized applications. The site successfully integrated itself into the supply chains of the personal care, nutrition, and specialty chemical industries, proving that industrial biotechnology could be both reliable and profitable.

Recent Years: The Biosurfactant Milestone

A key turning point occurred recently with the launch of an industrial-scale rhamnolipid biosurfactant production facility at the site. Rhamnolipids—nature-derived, biodegradable surfactants—represented a major success for Evonik’s sustainability-first strategy. This project proved that the Fermas site could successfully scale delicate biological processes to an industrial level.

2026: The Current Expansion

The groundbreaking ceremony marks the latest chapter, moving the site into the realm of complex pharmaceutical intermediates. This move signifies that the site is no longer just a production plant, but a sophisticated biotechnology campus integrated into the global pharmaceutical drug substance market.

Supporting Data: Why Fermentation Matters

The shift toward fermentation-based processes is driven by rigorous data regarding both efficiency and sustainability. Traditional chemical synthesis often relies on heavy use of organic solvents, high-pressure reactions, and energy-intensive distillation processes.

Sustainability Metrics

• Waste Reduction: Fermentation processes operate in aqueous environments, drastically reducing the reliance on volatile organic compounds (VOCs).
• Energy Efficiency: The Fermas site already utilizes 100% green electricity. By utilizing renewable and certified raw materials, the facility aligns with the "Green Chemistry" principles that are increasingly required by global regulatory bodies.
• Process Efficiency: Biotechnology allows for highly selective catalysis, meaning fewer byproducts are created during synthesis. This reduces the need for extensive downstream purification, saving both time and chemical waste.

Market Demand

The global CDMO market is experiencing an unprecedented surge, particularly for complex injectables and biological drugs. As pharmaceutical companies look to outsource the production of complex intermediates, they are prioritizing partners who can offer a secure, sustainable, and scalable manufacturing base. Evonik’s investment in Slovakia directly addresses this market gap.

Official Responses: Leadership Perspectives

During the groundbreaking ceremony, leadership emphasized that this project is as much about corporate identity as it is about physical infrastructure.

Lauren Kjeldsen, member of the management board and COO of Custom Solutions at Evonik, highlighted the dual nature of the strategy:

"Today is an important step in our strategy to expand our biotechnology platform and support our customers with innovative, scalable, and sustainable manufacturing solutions. Biotechnology demonstrates how economic growth and sustainability can go hand in hand."

Kjeldsen’s sentiment reflects the "Triple Bottom Line" approach that Evonik is championing—balancing profit, people, and the planet. By investing in Slovakia, the company is betting on the region’s technical talent and infrastructure.

Miroslav Havlik, general manager of Evonik Fermas, added:

"This investment demonstrates the company’s confidence in biotechnology and in Slovakia as a location where innovation turns into industrial scale products."

This endorsement of the Slovakian workforce and regulatory environment underscores the importance of regional hubs in a globalized supply chain. It suggests that Slovakia has successfully transitioned into a preferred destination for high-tech industrial investment, moving beyond simple manufacturing to become a hub for R&D-intensive production.

Implications: The Road Ahead

The implications of the Fermas expansion extend far beyond the borders of Slovakia.

For the Pharmaceutical Industry

The expansion provides a critical "de-risking" mechanism for pharmaceutical companies. By offering a robust, sustainable, and high-capacity site for intermediate production, Evonik provides a reliable anchor for drug development pipelines. As regulatory scrutiny on the carbon footprint of pharmaceutical manufacturing increases, having a partner like Evonik—which utilizes green energy and bio-based processes—becomes a competitive advantage.

For the Biotechnology Sector

This project is a bellwether for the industrialization of biotechnology. For years, the sector struggled with the "valley of death"—the difficulty of moving from a successful lab-scale process to an economically viable industrial-scale process. The Fermas site is effectively bridging this gap. By proving that complex biology can be managed at scale, Evonik is setting a standard for others to follow.

For Regional Development

The creation of 50 new jobs may seem modest in global terms, but in the context of the Fermas site, these are highly specialized roles. The expansion encourages the development of a local "cluster" effect—attracting talent to the region, fostering partnerships with local universities, and driving infrastructure improvements. It strengthens the reputation of the Slovenská Ľupča region as an essential part of the European biotech landscape.

For Evonik’s Future

For Evonik, this is a proof-of-concept. If the new facility reaches its projected milestones by 2028, it provides a blueprint for further expansions elsewhere. The strategy is clear: focus on "Custom Solutions," prioritize bio-based manufacturing, and embed sustainability into the very core of the product lifecycle.

Conclusion: A Blueprint for Sustainable Innovation

The ground-breaking at the Fermas site in Slovakia is more than a construction project; it is a manifestation of the future of industrial chemistry. In a world where the chemical industry is under immense pressure to reform its environmental impact, Evonik is demonstrating that the answer lies in biology.

By leveraging the power of fermentation and renewable resources, the company is creating a facility that is capable of meeting the sophisticated needs of the modern pharmaceutical industry while adhering to the highest standards of sustainability. As we look toward the 2028 completion date, the Fermas site stands as a testament to the idea that industrial scale and environmental stewardship are not mutually exclusive—rather, they are the essential components of the next generation of manufacturing.

Through this €80 million investment, Evonik is not just building a new plant; it is building the infrastructure for a cleaner, more efficient, and more innovative future.